A novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Glucocorticoid excess increases fat mass, preferentially within omental depots; yet circulating cortisol concentrations are normal in most patients with metabolic syndrome (MS). At a pre-receptor level, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activates cortisol from cortisone locally within adipose tissue, and inhibition of 11β-HSD1 in liver and adipose tissue has been proposed as a novel therapy to treat MS by reducing hepatic glucose output and adiposity. Using a transformed human subcutaneous preadipocyte cell line (Chub-S7) and human primary preadipocytes, we have defined the role of glucocorticoids and 11β-HSD1 in regulating adipose tissue differentiation. Human cells were differentiated with 1.0 μM cortisol (F), or cortisone (E) with or without 100 nM of a highly selective 11β-HSD1 inhibitor PF-877423. 11β-HSD1 mRNA expression increased across adipocyte differentiation (P<0.001, n=4), which was paralleled by an increase in 11β-HSD1 oxo-reductase activity (from nil on day 0 to 5.9±1.9 pmol/mg per h on day 16, P<0.01, n=7). Cortisone enhanced adipocyte differentiation; fatty acid-binding protein 4 expression increased 312-fold (P<0.001) and glycerol-3-phosphate dehydrogenase 47-fold (P<0.001) versus controls. This was abolished by co-incubation with PF-877423. In addition, cellular lipid content decreased significantly. These findings were confirmed in the primary cultures of human subcutaneous preadipocytes. The increase in 11β-HSD1 mRNA expression and activity is essential for the induction of human adipogenesis. Blocking adipogenesis with a novel and specific 11β-HSD1 inhibitor may represent a novel approach to treat obesity in patients with MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adipocyte differentiation from the inside out
Rosen, E. D., & MacDougald, O. A. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2066 · Cited by 2,607
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 3×
“…tolerance through reduced gluconeogenesis and hepatic glucose output (Kotelevtsev et al. 1997, Morton et al. 2001), while targeted overexpression of 11b-HSD1 in adipose tissue recapitulates features of the MS including central adiposity (Masuzaki et al. 2001).”
BackgroundDoes central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753 · cited 6×
“Whilst the cell line that we have used is subcutaneous in origin and the expression of 11b-HSD1 is higher in omental human preadipocytes (Bujalska et al. 1997b) and therefore we predict that the impact upon omental cells would be more Journal of Endocrinology (2008) 197, 297–307 pronounced.”
BackgroundMethodInfluentialSelf-citationMorton, N. M., Paterson, J. M., Masuzaki, H., Holmes, M. C., Staels, B., Fievet, C., Walker, B. R., Flier, J. S., Mullins, J. J., & Seckl, J. R. (2004) · Diabetes · doi:10.2337/diabetes.53.4.931 · Cited by 512 · cited 1×
“Conversely, global deletion of 11b-HSD1 caused reduced visceral fat accumulation and improved insulin sensitivity on a high fat diet (Kotelevtsev et al. 1997, Morton et al. 2004).”
BackgroundMasuzaki, H., Yamamoto, H., Kenyon, C. J., Elmquist, J. K., Morton, N. M., Paterson, J. M., Shinyama, H., Sharp, M. G. F., Fleming, S., Mullins, J. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17845 · Cited by 434 · cited 1×
“…tissue-targeted 11b-HSD1 overexpression develop visceral obesity, insulin resistance, hyperlipidaemia and hypertension without altering circulating glucocorticoids (Masuzaki et al. 2001, 2003), while mice with 11b-HSD1 overexpression in the liver develop MS without obesity (Paterson et al. 2004).”
BackgroundStewart, P. M., Boulton, A., Kumar, S., Clark, P. M. S., & Shackleton, C. H. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.3.5538 · Cited by 398
Self-citationOlefsky, J. M. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108231 · Cited by 277
Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes.
Slavin, B. G., Ong, J. M., & Kern, P. A. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41151-4 · Cited by 261
Walker, E. A., Clark, A. M., Hewison, M., Ride, J. P., & Stewart, P. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011142200 · Cited by 65 · cited 1×
“…oxo-reductase activity with a Km for cortisone in Chubb-S7 cells of 100 nM which is similar to the reports in other 11b-HSD1-expressing cell systems (Monder & Lakshmi 1989, Ricketts et al. 1998) including studies on the recombinant enzyme (KmZ333 nM;Walker et al. 2001, Shafqat et al. 2003).”
MethodSelf-citation
Cited by
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
11β-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action
Chapman, K., Holmes, M., & Seckl, J. (2013) · Physiological Reviews · doi:10.1152/physrev.00020.2012 · Cited by 887
The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis
Anagnostis, P., Athyros, V. G., Tziomalos, K., Karagiannis, A., & Mikhailidis, D. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0370 · Cited by 613
Mechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
Transcriptional Regulation of Adipogenesis
de Sá, P. M., Richard, A. J., Hang, H., & Stephens, J. M. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c160022 · Cited by 360
Metadata
- Authors
- Bujalska, I. J., Gathercole, L. L., Tomlinson, J. W., Darimont, C., Ermolieff, J., Fanjul, A. N., Rejto, P. A., & Stewart, P. M.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2008-03-04
- Volume
- 197
- Issue
- 2
- Pages
- 297-307
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2145329718
- Cited by
- 84
- References
- 9
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. https://app.cochat.ai/papers/10.1677/joe-08-0050
- The paper
- Bujalska, I. J., Gathercole, L. L., Tomlinson, J. W., Darimont, C., Ermolieff, J., Fanjul, A. N., Rejto, P. A., & Stewart, P. M. (2008). A novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. Journal of Endocrinology. https://doi.org/10.1677/joe-08-0050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.